129 related articles for article (PubMed ID: 19052491)
21. Add-back medrogestone does not prevent bone loss in premenopausal women treated with goserelin.
Sillem M; Parviz M; Woitge HW; Kiesel L; Ulrich U; von Holst T; Runnebaum B; Ziegler R; Seibel MJ
Exp Clin Endocrinol Diabetes; 1999; 107(6):379-85. PubMed ID: 10543415
[TBL] [Abstract][Full Text] [Related]
22. Changes of bone markers during long-term intravenous calcitriol therapy in maintenance dialysis patients.
Lee SH; Huang TS; Hsieh SJ
Miner Electrolyte Metab; 1996; 22(4):219-23. PubMed ID: 8807625
[TBL] [Abstract][Full Text] [Related]
23. Biochemical markers of bone metabolism in infants and children under intravenous corticosteroid therapy.
Siomou E; Challa A; Tzoufi M; Papadopoulou ZL; Lapatsanis PD; Siamopoulou A
Calcif Tissue Int; 2003 Oct; 73(4):319-25. PubMed ID: 12874699
[TBL] [Abstract][Full Text] [Related]
24. Is skeletal responsiveness to thyroid hormone altered in primary osteoporosis or following estrogen replacement therapy?
Langdahl BL; Loft AG; Møller N; Weeke J; Eriksen EF; Mosekilde L; Charles P
J Bone Miner Res; 1997 Jan; 12(1):78-88. PubMed ID: 9240729
[TBL] [Abstract][Full Text] [Related]
25. [The risk factors and bone mineral density in women on long-term levothyroxine treatment].
López Alvarez MB; Hawkins F; Rigopoulou D; Martínez G; Jodar E; Estenoz J; Ortuño B; Arnaiz F
Med Clin (Barc); 1999 Jan; 112(3):85-9. PubMed ID: 10074614
[TBL] [Abstract][Full Text] [Related]
26. Change in serum undercarboxylated osteocalcin concentration in bilaterally oophorectomized women.
Yasui T; Uemura H; Tomita J; Miyatani Y; Yamada M; Kuwahara A; Matsuzaki T; Maegawa M; Miura M; Irahara M
Maturitas; 2007 Mar; 56(3):288-96. PubMed ID: 17030103
[TBL] [Abstract][Full Text] [Related]
27. Effects of intravenous EDTA treatment on serum parathyroid hormone (1-84) and biochemical markers of bone turnover.
Guldager B; Brixen KT; Jørgensen SJ; Nielsen HK; Mosekilde L; Jelnes R
Dan Med Bull; 1993 Nov; 40(5):627-30. PubMed ID: 8299406
[TBL] [Abstract][Full Text] [Related]
28. The course of hypercalciuria and related markers of bone metabolism parameters associated with corticosteroid treatment.
Duzen O; Erkoc R; Begenik H; Soyoral YU; Aldemir MN
Ren Fail; 2012; 34(3):338-42. PubMed ID: 22260330
[TBL] [Abstract][Full Text] [Related]
29. [Bone metabolism in primary hypothyroidism in the adult].
Foscolo G; Roiter I; De Menis E; Da Rin G; Legovini P; Conte N
Minerva Endocrinol; 1991; 16(1):7-10. PubMed ID: 1944017
[TBL] [Abstract][Full Text] [Related]
30. Modulatory effects of Aroclors 1221 and 1254 on bone turnover and vertebral histology in intact and ovariectomized rats.
Yilmaz B; Seyran AD; Sandal S; Aydin M; Colakoglu N; Kocer M; Carpenter DO
Toxicol Lett; 2006 Oct; 166(3):276-84. PubMed ID: 16978806
[TBL] [Abstract][Full Text] [Related]
31. Effects of levothyroxine suppressive therapy on bone mineral density in premenopausal women.
Larijani B; Gharibdoost F; Pajouhi M; Sadjadi A; Aghakhani S; Eshraghian R; Akrami SM; Maalouf G
J Clin Pharm Ther; 2004 Feb; 29(1):1-5. PubMed ID: 14748891
[TBL] [Abstract][Full Text] [Related]
32. Nyctohemeral changes in bone turnover assessed by serum bone Gla-protein concentration and urinary deoxypyridinoline excretion: effects of growth and ageing.
Eastell R; Simmons PS; Colwell A; Assiri AM; Burritt MF; Russell RG; Riggs BL
Clin Sci (Lond); 1992 Sep; 83(3):375-82. PubMed ID: 1327658
[TBL] [Abstract][Full Text] [Related]
33. Effects of levothyroxine therapy on bone mineral density and bone turnover markers in premenopausal women with thyroid cancer after thyroidectomy.
Bin-Hong D; Fu-Man D; Yu L; Xu-Ping W; Bing-Feng B
Endokrynol Pol; 2020; 71(1):15-20. PubMed ID: 31681976
[TBL] [Abstract][Full Text] [Related]
34. Suppressive therapy with levothyroxine for solitary thyroid nodules.
Reverter JL; Lucas A; Salinas I; Audí L; Foz M; Sanmartí A
Clin Endocrinol (Oxf); 1992 Jan; 36(1):25-8. PubMed ID: 1559296
[TBL] [Abstract][Full Text] [Related]
35. Levothyroxine treatment in pediatric benign thyroid nodules.
Corrias A; Mussa A; Wasniewska M; Segni M; Cassio A; Salerno M; Gastaldi R; Vigone MC; Bal M; Matarazzo P; Weber G; De Luca F
Horm Res Paediatr; 2011; 75(4):246-51. PubMed ID: 21135537
[TBL] [Abstract][Full Text] [Related]
36. Effect of low- and high-dose levothyroxine on thyroid nodule volume: a crossover placebo-controlled trial.
Koc M; Ersoz HO; Akpinar I; Gogas-Yavuz D; Deyneli O; Akalin S
Clin Endocrinol (Oxf); 2002 Nov; 57(5):621-8. PubMed ID: 12390336
[TBL] [Abstract][Full Text] [Related]
37. Effects of suppressive doses of levothyroxine treatment on sex-hormone-binding globulin and bone metabolism.
Lecomte P; Lecureuil N; Osorio-Salazar C; Lecureuil M; Valat C
Thyroid; 1995 Feb; 5(1):19-23. PubMed ID: 7787428
[TBL] [Abstract][Full Text] [Related]
38. [Levothyroxine treatment of the solitary thyroid nodule].
Almodóvar Ruiz F; Maldonado Castro G; de Luis D; Lahera M; Varela da Costa C
An Med Interna; 2000 Feb; 17(2):99-101. PubMed ID: 10829467
[TBL] [Abstract][Full Text] [Related]
39. Bone metabolism in patients with differentiated thyroid carcinoma receiving suppressive levothyroxine treatment.
Mikosch P; Obermayer-Pietsch B; Jost R; Jauk B; Gallowitsch HJ; Kresnik E; Leb G; Lind P
Thyroid; 2003 Apr; 13(4):347-56. PubMed ID: 12804103
[TBL] [Abstract][Full Text] [Related]
40. Thyroid hormone treatment aiming at reduced, but not suppressed, serum thyroid-stimulating hormone levels in nontoxic goitre: effects on bone metabolism amongst premenopausal women.
Knudsen N; Faber J; Sierbaek-Nielsen A; Vadstrup S; Sørensen HA; Hegedüs L
J Intern Med; 1998 Feb; 243(2):149-54. PubMed ID: 9566644
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
